Sight Sciences' Cataract Surgery Tech Shows Consistent Lowering Of Eye Pressure, Medication Use - Sight S

Sight Sciences Inc (NASDAQ:SGHT) published two-year results of the so-called "Romeo" study of the OMNI Surgical System.

The OMNI Surgical System technology in standalone and combination-cataract surgery demonstrated that the significant reductions in Intraocular Pressure (IOP) and medication usage observed at 12 months were also witnessed at 24 months.
In addition, there were no serious or unanticipated adverse events during the two-year study.
Patients with mild-moderate glaucoma received outflow restorative procedures enabled with the OMNI Surgical System technology, either during cataract surgery (n = 43) or as a standalone treatment (n = 29).
Patients were divided into high-baseline IOP (pre-operative IOP > 18 mmHg, n = 34) and low-baseline IOP cohorts (pre-operative IOP ≤ 18 mmHg, n = 38).
Average IOP in the high baseline IOP cohort fell 31% (from 21.9 mmHg to 15.2 mmHg) at two years, which included an average reduction of 28% among combination cataract patients (n = 17) and an average reduction of 33% among standalone patients (n = 17).
The study also observed an average 33% reduction in medication usage among all patients at 24 months.
The OMNI Surgical System enables surgeons to provide minimally invasive, implant-free surgery to reduce IOP in adults with primary open-angle glaucoma.

Price Action: SGHT shares are down 0.43% at $9.28 on the last check Tuesday via Benzinga Pro.

To add Benzinga News as your preferred source on Google, click here.